Benzinga | Jan 7, 2022 01:05PM EST

Maxim Group Initiates Coverage On NeuroSense Therapeutics with Buy Rating, Announces Price Target of $7

Maxim Group analyst Naz Rahman initiates coverage on NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy rating and announces Price Target of $7.